- Home
- BQ vs CNSP Comparison
BQ vs CNSP Comparison
Compare BQ & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BQ | CNSP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.5M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BQ | CNSP |
|---|---|---|
| Price | $0.72 | $5.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 33.8K | 2.0K |
| Earning Date | 07-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $1.90 |
| 52 Week High | $72.74 | $10.54 |
Technical Indicators
Market Signals| Indicator | BQ | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 42.89 |
| Support Level | $0.70 | $4.88 |
| Resistance Level | $0.89 | $5.52 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.12 | 31.89 |
Price Performance
Historical ComparisonAbout BQ Boqii Holding Limited representing
Boqii Holding Ltd is a pet-focused platform in China. It offer a truly one-stop destination that pet parents in China may go to get everything it need for their pets and share their passion for pet parenting. It operate a pet-focused online retail business in China's pet market in terms of GMV. The company operates in single segment. This segment is engaged in pet products sales and online marketing and information services and other. All the company's revenues is derived from The PRC.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.